Cat. No. 3599
Alternative Name: Mubritinib
Chemical Name: 1-[4-[4-[[2-[(1E)-2-[4-(trifluorome
Biological ActivityPotent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Sridhar et al (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 4 397. PMID: 12850190.
Nagasawa et al (2006) Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int.J.Urol. 13 585.
Spector et al (2007) Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 9 205.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: TAK 165, supplier, Potent, selective, ErbB2, inhibitors, Epidermal, Growth, Factor, Receptors, Her, EGFR, Receptor, Tyrosine, Kinases, RTKs, TAK165
Find multiple products by catalog number
New Products in this Area
High affinity and selective ALK and ROS1 inhibitor6bK
Insulin degrading enzyme (IDE) inhibitorCrizotinib
Potent c-MET/ALK inhibitorAC 710
Potent and selective PDGFR family inhibitorSPP 86
Potent RET inhibitorSGX 523
Selective and potent c-MET kinase inhibitor
October 17-21, 2015